Mary Fitzpatrick, BSN, MPH, ANP

More documents

Recommendations

Info

All patients prescribed dalfampridine at the Portland VA Medical Center from 10/01/10-09/30/11 ◦ T25FTW, ◦ MSWS-12, ◦ two minute timed walk (2MTW) ◦ Community Integration Questionnaire (CIQ) Baseline assessment prior to taking dalfampridine. Individuals reporting a favorable response to dalfampridine at 3-4 weeks continued to take the drug All measures repeated at 1-4 months and at follow-up MS clinic visits. Measures were compared with baseline using paired t- tests.
Time (seconds) 25 Foot Timed Walk 50 45 Mean: 13.86 ± 9.55 N = 23 Mean: 10.55 ± 6.18 N = 22, P = 0.002 Mean: 9.40 ± 2.75 N = 16, P = 0.071 40 35 30 25 20 15 10 5 0 Baseline 1-4 months 5-10 months
Page 2 and 3: Mary Fitzpatrick, ANP, MSCN Michell
Page 4 and 5: Michelle Cameron, MD, PT has receiv
Page 6 and 7: Background Walking impairment in M
Page 9 and 10: Very varied but… @ initial presen
Page 12 and 13: Sensory changes - particularly prop
Page 14: Instrumented walkway Gait lab Gyr
Page 19: 01/22/2010 the FDA approved dalfamp
Page 23 and 24: Distance (feet) Two Minute Timed Wa
Page 25 and 26: 1. 39 individuals were prescribed d
Page 27 and 28: 75% complain of balance abnormaliti
Page 31 and 32: % Falls in 12 months How many peopl
Page 33 and 34: Falling in People with MS Aged 45-9
Page 35 and 36: Falls in Veterans with MS in VISN20
Page 37 and 38: Divided attention Reduced muscular
Page 40 and 41: Based on ◦ General common pathoph
Page 42 and 43: Enhance input ◦ TENS, strap or br
Page 44 and 45: Light touch - increases propriocept
Page 46: Walking and talking Walking and hea
Page 53: Many Veterans with MS have impaired

Mary Fitzpatrick, BSN, MPH, ANP

Create successful ePaper yourself

Delete template?

Save as template?